Endotracheal and Aerosol Administrations of Ceftazidime in Patients with Nosocomial Pneumonia: Pharmacokinetics and Absolute Bioavailability

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1992 Jul 1

PMID 1510435

Citations 13

Authors

F Bressolle

J E de La Coussaye

R Ayoub

D Fabre

R Gomeni

G Saissi

J J Eledjam

M GALTIER

Affiliations

Soon will be listed here.

Abstract

Pharmacokinetic studies on ceftazidime, an aminothiazole cephalosporin with a wide spectrum of antibacterial activity, including activity against Pseudomonas aeruginosa, were performed in patients with nosocomial pneumonia. The concentration-time profiles of ceftazidime in plasma, urine, and bronchial secretions of 12 patients were investigated after intravenous (i.v.) (n = 12), endotracheal (n = 10), and aerosol (n = 5) administrations. In all cases a 1-g dose was administered. Concentrations of drug in all samples were assayed by high-performance liquid chromatography with UV detection. The elimination of the drug from the blood followed a biexponential (i.v. administration) or a monoexponential (endotracheal and aerosol administrations) decay, with an elimination half-life of 6 h and a total body clearance of 4.2 liters/h. The apparent volume of distribution was 0.36 liter/kg of body weight. Renal clearance of the drug accounted for 58% of the total clearance; 66% +/- 17.7%, 33.5% +/- 17.3%, and 6.59% +/- 3.45% of the administered dose were eliminated in urine as parent drug after i.v., endotracheal, and aerosol administrations, respectively. The absolute bioavailabilities were 0.47 and 0.08 for endotracheal and aerosol administrations, respectively. Very high concentrations were found in bronchial secretions after local administration. The MICs for 90% of the most important pathogens responsible for nosocomial infections were exceeded by concentrations in bronchial secretion for up to 12 h after i.v. infusion and for up to 24 h after endotracheal and aerosol administrations.

Citing Articles

Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review-Part I.

Finazzi S, Luci G, Olivieri C, Langer M, Mandelli G, Corona A Antibiotics (Basel). 2022; 11(9).

PMID: 36139944 PMC: 9495190. DOI: 10.3390/antibiotics11091164.

Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia.

Das S, Zhou D, Nichols W, Townsend A, Newell P, Li J Eur J Clin Pharmacol. 2019; 76(3):349-361.

PMID: 31836928 PMC: 7223046. DOI: 10.1007/s00228-019-02804-z.

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.

Das S, Li J, Riccobene T, Carrothers T, Newell P, Melnick D Antimicrob Agents Chemother. 2019; 63(4).

PMID: 30670413 PMC: 6437548. DOI: 10.1128/AAC.02187-18.

Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.

Goncalves-Pereira J, Povoa P Crit Care. 2011; 15(5):R206.

PMID: 21914174 PMC: 3334750. DOI: 10.1186/cc10441.

Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers.

Ferrari F, Liu Z, Lu Q, Becquemin M, Louchahi K, Aymard G Intensive Care Med. 2008; 34(9):1718-23.

PMID: 18542922 DOI: 10.1007/s00134-008-1126-4.

References

Klick J, du Moulin G, Hedley-Whyte J, TERES D, Bushnell L, Feingold D . Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. J Clin Invest. 1975; 55(3):514-9. PMC: 301778. DOI: 10.1172/JCI107957. View

Karhunen M, KOSKELA O, HALLSTROM K . Single dose of tinidazole in prophylaxis in infections following vaginal surgery. J Antimicrob Chemother. 1981; 8(4):283-90. DOI: 10.1093/jac/8.4.283. View

Aguilera D, Coupry A, Holzapfel L, Karlin P, Giudicelli D, Gontier D . [Serum and bronchial concentrations of netilmicin during its continuous intratracheal administration]. Pathol Biol (Paris). 1986; 34(5 Pt 2):657-62. View

Klastersky J, Cappel R, Noterman J, Snoeck J, Geuning C, Mouawad E . Endotracheal gentamicin for the prevention of bronchial infections in patients with tracheotomy. Int J Clin Pharmacol. 1973; 7(4):279-86. View

Davies B, MAESEN F, van Noord J . Treatment of chronic and recurrent respiratory infections with intramuscular ceftazidime. J Antimicrob Chemother. 1983; 12 Suppl A:1-8. DOI: 10.1093/jac/12.suppl_a.1. View

Leroy A, Leguy F, Borsa F, SPENCER G, Fillastre J, Humbert G . Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother. 1984; 25(5):638-42. PMC: 185604. DOI: 10.1128/AAC.25.5.638. View

Bergogne-Berezin E, Pierre J, Berthelot G, Kafe H, Even P, Gibert C . [Bronchial diffusion of new anti-pseudomonal beta-lactams. Clinical significance]. Pathol Biol (Paris). 1984; 32(5):421-5. View

Rubinstein E, Green M, Modan M, Amit P, Bernstein L, Rubinstein A . The effects of nosocomial infections on the length and costs of hospital stay. J Antimicrob Chemother. 1982; 9 Suppl A:93-100. DOI: 10.1093/jac/9.suppl_a.93. View

Feeley T, du Moulin G, Hedley-Whyte J, Bushnell L, Gilbert J, Feingold D . Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med. 1975; 293(10):471-5. DOI: 10.1056/NEJM197509042931003. View

10.

Erttmann M, Ullmann U, Koch E . Results of a clinical and pharmacokinetic study of ceftazidime in patients with postoperative pneumonia on assisted ventilation. J Hosp Infect. 1990; 15 Suppl A:55-9. DOI: 10.1016/0195-6701(90)90080-8. View

11.

Johanson Jr W, Seidenfeld J, de los Santos R, Coalson J, Gomez P . Prevention of nosocomial pneumonia using topical and parenteral antimicrobial agents. Am Rev Respir Dis. 1988; 137(2):265-72. DOI: 10.1164/ajrccm/137.2.265. View

12.

Taburet A, Steimer J, Doucet D, Singlas E . [Mean residence time in the body. A new pharmacokinetic parameter?]. Therapie. 1986; 41(1):1-10. View

13.

Haley R, Culver D, White J, Morgan W, Emori T, Munn V . The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol. 1985; 121(2):182-205. DOI: 10.1093/oxfordjournals.aje.a113990. View

14.

Greenfield S, TERES D, Bushnell L, Hedley-Whyte J, Feingold D . Prevention of gram-negative bacillary pneumonia using aerosol polymyxin as prophylaxis. I. Effect on the colonization pattern of the upper respiratory tract of seriously ill patients. J Clin Invest. 1973; 52(11):2935-40. PMC: 302562. DOI: 10.1172/JCI107490. View

15.

Strandvik B, MALMBORG A, Alfredson H, Ericsson A . Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. J Antimicrob Chemother. 1983; 12 Suppl A:283-7. DOI: 10.1093/jac/12.suppl_a.283. View

16.

Kercsmar C, Stern R, Reed M, Myers C, Murdell D, Blumer J . Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response. J Antimicrob Chemother. 1983; 12 Suppl A:289-95. DOI: 10.1093/jac/12.suppl_a.289. View

17.

Turner A, Pedler S, Carswell F, SPENCER G, Speller D . Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. J Antimicrob Chemother. 1984; 14(5):521-7. DOI: 10.1093/jac/14.5.521. View

18.

KELLY H, Menendez R, Fan L, Murphy S . Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr. 1982; 100(2):318-21. DOI: 10.1016/s0022-3476(82)80664-1. View

19.

Fagon J, Chastre J, HANCE A, Guiguet M, Trouillet J, Domart Y . Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis. 1988; 138(1):110-6. DOI: 10.1164/ajrccm/138.1.110. View